Skip to main content Skip to megamenu (after main content)
Meet us next:   BIO International Convention 2025 – 16-19 June 2025  ●  more on our events calendar

Corporate News tagged:

Drug Discovery (2)

REPROCELL join Medicines Discovery Catapult’s Virtual R&D network to accelerate drug development

12 March 2019

REPROCELL has joined Medicines Discovery Catapult’s Virtual R&D platform – a unique national network of consultants, private sector CROs, expert labs and public sector centres of excellence, providing medicines discovery expertise, services and virtual programme management.

ROSLINCT and REPROCELL awarded £1.2 million from Innovate UK for clinical-grade stem cell production

10 October 2018

Learn more about the partnership between REPROCELL and ROSLINCT aiming to improve efficiency of induced pluripotent stem cell production

REPROCELL’s Dr David Bunton on April 2018 Trade Mission to China with Scottish First Minister Nicola Sturgeon

18 April 2018

REPROCELL Europe’s CEO, Dr David Bunton, was part of the trade mission to China undertaken by the Scottish First Minister, the Rt. Hon. Nicola Sturgeon MSP, 9-13 April 2018.

Derek Mackay, SNP Cabinet Secretary for Finance and the Constitution, visits REPROCELL Europe, Glasgow

06 April 2018

Read about REPROCELL's visit from Derek Mackay, the Scottish National Party’s Cabinet Secretary for Finance and the Constitution, on 05 April 2017

REPROCELL’s David Bunton addresses the Scottish Parliament

21 March 2018

Discussing how sectors, such as life science, are affected by Scotland’s economic performance and what actions are required to make the economy more inclusive, innovative and international. Topics include key factors in company success, SME’s and government partnership.

Patient-derived tumor organoids recapitulate clinical treatments

14 March 2018

REPROCELL is currently working to develop a highly predictive three-dimensional (3D) human micro-intestine model that can be used to test new drugs for the treatment of IBD and gastrointestinal cancers.

REPROCELL Chooses Science Exchange as the Preferred Partner to Increase Accessibility of its Predictive Drug Discovery Services

08 November 2017

PALO ALTO, CA, November 8, 2017 – Science Exchange, the world’s leading and most secure enterprise platform for outsourced research services and procurement of human biospecimens, announced today that REPROCELL has selected the Science Exchange platform.

Article by Dr David Bunton (co-authored) in the European Pharmaceutical Review, Autumn 2017

27 September 2017

REPROCELL Europe Ltd’s CEO, Dr David Bunton, has co-authored an article titled New Strategy that has been published in the European Pharmaceutical Review, Autumn 2017.

Nicola Sturgeon: interview at the official opening of REPROCELL’s Centre for Predictive Drug Discovery (YouTube video)

10 August 2017

Video: First Minister Nicola Sturgeon officially opened the new European headquarters of a life sciences company which is set to generate 15 new jobs and safeguard a further three following new investment.

Press Release: Nicola Sturgeon, First Minister of Scotland, opens REPROCELL European Headquarters in Glasgow

10 August 2017

REPROCELL Europe Ltd (REPROCELL), a leading provider of products and services for research in stem cells, drug discovery, human tissues and 3D cell culture and a member of the REPROCELL Group, has opened its European headquarters in Glasgow, UK.

REPROCELL Europe’s CEO Dr David Bunton presented at NC3Rs workshop: Human tissue models for cancer research

03 March 2017

REPROCELL Europe’s CEO, Dr David Bunton presented at the recent NC3Rs meeting on the use of human tissues in cancer research. The conference considered the potential for human tissue models to help reduce clinical drug attrition and provide more relevant models of cancer

REPROCELL Inc CEO meets with Scottish Cabinet Secretary Fiona Hyslop in Japan

14 February 2017

Read about the REPROCELL CEO's meeting with Fiona Hyslop, Cabinet Secretary for Culture, Tourism and External Affairs for the Scottish Government

Scottish Enterprise Association Honours REPROCELL with Annual Awards Nomination

07 February 2017

Read about REPROCELL CEO Dr David Bunton's nomination for the Scottish Enterprise Association Life Science Business Leadership Award

Announcement on the initiation of a new business from the collaboration and commercialization agreement with Steminent Biotherapeutics Inc. for cell therapy

11 November 2016

Read about REPROCELL's partnership with Steminent Biotherapeutics to develop and commercialize Steminent’s allogeneic stem cell therapy product Stemchymal.

Latest Proteon and Biopta publication demonstrates Proteon's Vonapanitase effects in human cephalic veins

13 May 2016

Proteon Therapeutics Announces Publication in Cardiovascular Pharmacology: Open Access Describing Promising Nonclinical Results for Vonapanitase in Improving Arteriovenous Fistula (AVF) Maturation and patency in Chronic Kidney Disease (CKD) Patients.

Proteon and Biopta publication shows promising nonclinical results on Proteon's Vonapanitase

21 April 2016

Proteon Therapeutics Announces Publication in the Journal of Cardiovascular Pharmacology of Promising Nonclinical Results for Vonapanitase in Peripheral Artery Disease.

REPROCELL acquires Biopta to expand its drug discovery services

25 November 2015

The Japanese regenerative medicine company REPROCELL Inc. has announced the acquisition of the Scottish life sciences company, Biopta.

Biopta co-authors research in the European Respiratory Journal

18 November 2015

The impact of fresh human tissue studies for translational work performed at Biopta has once again been demonstrated with this latest publication at the European Respiratory Society.

REPROCELL announces publication of a research report on “3D Skin Model Construction,” submitted to the International Scientific Journal “Molecular Cancer Therapeutics” by REPROCELL and others

19 October 2015

Read more about REPROCELL CSO Professor Stefan Przyborski's latest publication on 3D Skin Model Construction published in Molecular Cancer Therapeutics

New paper demonstrates formation of spontaneously active neuronal networks by stem cell derived neurons in 3D Alvetex Scaffold culture system

05 March 2015

A recently published paper by Imogen Smith et al. demonstrates the use of the Alvetex platform to culture 3D differentiated human neural stem cells.